U.S. markets closed
  • S&P 500

    4,701.21
    +14.46 (+0.31%)
     
  • Dow 30

    35,754.75
    +35.32 (+0.10%)
     
  • Nasdaq

    15,786.99
    +100.07 (+0.64%)
     
  • Russell 2000

    2,271.71
    +17.92 (+0.80%)
     
  • Crude Oil

    72.71
    +0.66 (+0.92%)
     
  • Gold

    1,784.30
    -0.40 (-0.02%)
     
  • Silver

    22.44
    -0.08 (-0.35%)
     
  • EUR/USD

    1.1349
    +0.0077 (+0.68%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • GBP/USD

    1.3210
    -0.0032 (-0.24%)
     
  • USD/JPY

    113.7100
    +0.1700 (+0.15%)
     
  • BTC-USD

    50,640.31
    -71.58 (-0.14%)
     
  • CMC Crypto 200

    1,320.28
    +15.16 (+1.16%)
     
  • FTSE 100

    7,337.05
    -2.85 (-0.04%)
     
  • Nikkei 225

    28,860.62
    +405.02 (+1.42%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Oscar Health, Inc. (OSCR) Investigation

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / June 10, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Oscar Health, Inc. ('Oscar' or 'the Company') (NYSE:OSCR). Investors who purchased Oscar securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/oscr.

The investigation concerns whether Oscar and certain of its officers and/or directors have violated federal securities laws.

On or around March 3, 2021, Oscar conducted its initial public offering ("IPO"), selling approximately 37 million shares of stock priced at $39.00 per share. Then, on May 13, 2021, Oscar reported its earnings for the first time since the Company's IPO. Among other results, Oscar reported a loss of $87.4 million, or $0.98 per share, for the first quarter of 2021, compared to analysts estimates that the Company would report a loss of only $0.53 per share. On this news, Oscar's stock price fell $1.63 per share, or 7.36%, to close at $20.51 per share on May 13, 2021.

If you are aware of any facts relating to this investigation, or purchased Oscar shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/oscr. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/651273/Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-of-Oscar-Health-Inc-OSCR-Investigation